Marko Duvnjak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marko Duvnjak has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Tajana Pavic
Department of Gastroenterology and Hepatology, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia
5 shared publications - Davor Hrabar
Zavod za gastroenterologiju i hepatologiju, Klinika za unutarnje bolesti, Klinicka bolnica "Sestre milosrdnice", Zagreb, Hrvatska
4 shared publications Lucija Virović
4 shared publications- Neven Ljubičić
Department of Gastroenterology, Clinical Hospital Center Sestre Milosrdnice, 10000 Zagreb, Croatia
4 shared publications Marko Nikolić
2 shared publicationsAlen Biscanin
1 shared publication
Latest Publications
- 1 April 2015
- Published by Elsevier in Gastroenterology
- Vol. 148 (4)
Sa1332 Ghrelin Is Elevated in Patients With Biliary Obstruction
- 1 April 2015
- Published by Elsevier in Gastroenterology
- Vol. 148 (4)
Sa1332 Ghrelin Is Elevated in Patients With Biliary Obstruction
- 7 July 2011
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 56 (12) , 3655-3663
Nonalcoholic Fatty Liver Disease Markers Are Associated with Insulin Resistance in Type 1 Diabetes
Nonalcoholic fatty liver disease (NAFLD) has been associated with the insulin resistance. To explore the relationship between markers of NAFLD, namely concentrations of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALK), γ-glutamyltransferase (GGT), ferritin and bilirubin and insulin resistance in type 1 diabetes. Our study included 353 patients with type 1 diabetes. Insulin sensitivity was measured with estimated glucose disposal rate calculated using the equation: eGDR = 24.31 − (12.22 × WHR) − (3.29 × HT) − (0.57 × HbA1c); WHR = waist to hip ratio, HT = hypertension. Correlations and multiple logistic regressions analysis were performed to identify the relationships between NAFLD associated markers and eGDR, individual components of insulin resistance and risk of insulin resistance. AST, ALT, AST-to-ALT ratio, ALK and ferritin significantly correlated with insulin resistance measured by eGDR (r = −0.13, −0.14, 0.13, −0.18, and −0.24, respectively; all P < 0.05), and with individual components of insulin resistance, most notably WHR. In a multiple logistic regression model adjusted according to age, sex, duration of diabetes and BMI, increased levels of AST, ALT and ALK resulted in an increased risk for the development of insulin resistance in our subjects (OR = 1.03, 1.02, and 1.01, respectively; all P < 0.05). These findings indicate that higher levels of ALT, AST and ALK are additional markers of insulin resistance in type 1 diabetes and suggest that those subjects must be considered as potentially affected not only by a hepatic but also by a multisystemic disease through altered insulin sensitivity.
- 7 July 2011
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 56 (12) , 3655-3663
Nonalcoholic Fatty Liver Disease Markers Are Associated with Insulin Resistance in Type 1 Diabetes
Nonalcoholic fatty liver disease (NAFLD) has been associated with the insulin resistance. To explore the relationship between markers of NAFLD, namely concentrations of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALK), γ-glutamyltransferase (GGT), ferritin and bilirubin and insulin resistance in type 1 diabetes. Our study included 353 patients with type 1 diabetes. Insulin sensitivity was measured with estimated glucose disposal rate calculated using the equation: eGDR = 24.31 − (12.22 × WHR) − (3.29 × HT) − (0.57 × HbA1c); WHR = waist to hip ratio, HT = hypertension. Correlations and multiple logistic regressions analysis were performed to identify the relationships between NAFLD associated markers and eGDR, individual components of insulin resistance and risk of insulin resistance. AST, ALT, AST-to-ALT ratio, ALK and ferritin significantly correlated with insulin resistance measured by eGDR (r = −0.13, −0.14, 0.13, −0.18, and −0.24, respectively; all P < 0.05), and with individual components of insulin resistance, most notably WHR. In a multiple logistic regression model adjusted according to age, sex, duration of diabetes and BMI, increased levels of AST, ALT and ALK resulted in an increased risk for the development of insulin resistance in our subjects (OR = 1.03, 1.02, and 1.01, respectively; all P < 0.05). These findings indicate that higher levels of ALT, AST and ALK are additional markers of insulin resistance in type 1 diabetes and suggest that those subjects must be considered as potentially affected not only by a hepatic but also by a multisystemic disease through altered insulin sensitivity.
- 1 June 2010
- Vol. 34 (2) , 757-62
The role of endoscopic ultrasound in evaluation of gastric subepithelial lesions.
A subepithelial mass is a common finding during endoscopic procedures. Endoscopic ultrasound (EUS) is an important diagnostic modality in the evaluation of subepithelial lesions of the gastrointestinal tract. EUS is the diagnostic test of choice to assess the size, margins, the layer of origin, echotexture, and to differentiate between an intramural and extramural lesion. However, the EUS imaging lacks the specificity. EUS-guided fine needle aspiration (EUS-FNA) or core biopsy can help establish a tissue diagnosis and potentially characterize malignant risk. The aim of this article is to review the diagnosis and management of the most common subepithelial gastric lesions with an emphasis on the role of endoscopic ultrasound.
- 1 June 2010
- Vol. 34 (2) , 757-62
The role of endoscopic ultrasound in evaluation of gastric subepithelial lesions.
A subepithelial mass is a common finding during endoscopic procedures. Endoscopic ultrasound (EUS) is an important diagnostic modality in the evaluation of subepithelial lesions of the gastrointestinal tract. EUS is the diagnostic test of choice to assess the size, margins, the layer of origin, echotexture, and to differentiate between an intramural and extramural lesion. However, the EUS imaging lacks the specificity. EUS-guided fine needle aspiration (EUS-FNA) or core biopsy can help establish a tissue diagnosis and potentially characterize malignant risk. The aim of this article is to review the diagnosis and management of the most common subepithelial gastric lesions with an emphasis on the role of endoscopic ultrasound.
- 1 December 2009
- p. 5-9
[Endoscopic ultrasonography in the diagnosis of choledocholithiasis].
Endoscopic retrograde cholangiopancreatography (ERCP) has been considered a gold standard in the diagnosis of choledocholithiasis; however, the incidence of complications is high. In literature reports, the morbidity rate ranges from 5% to 19% and mortality rate from 0.1% to 1.3%, therefore an effective but less invasive new method of diagnosing choledocholithiasis is required. In a number of trials, endoscopic ultrasonography (EUS) has been shown to be a less invasive method with excellent sensitivity of 94% and specificity of 95%. The aim of this study was to estimate the sensitivity and specificity of EUS in patients with suspected choledocholithiasis and to establish its role in the algorithm for diagnosing choledocholithiasis. Patient files were retrospectively reviewed in 209 patients with a clinical picture and ultrasonography findings suggestive of choledocholithiasis, admitted to Sestre milosrdnice University Hospital during a six-month period (Sep 1, 2007 - Feb 29, 2008) and submitted to ERCP within 72 hours of admission. In 125 patients with abdominal ultrasonography findings suggestive of choledocholithiasis (biliary obstruction without clear evidence of calculi), EUS was performed before ERCR. Choledocholithiasis or biliary sludge was identified in 66 (62.3%) patients, 29 (27.3%) patients were free from biliary abnormalities, and 11 (10.4%) patients had stenosis of different etiology. In 64 of 66 (96.9%) patients, the diagnosis was confirmed by ERCP. Another two (3.1%) patients had no evidence of choledocholithiasis on ERCP. There were no complications related to EUS. EUS is an effective method for diagnosing choledocholithiasis with a sensitivity and specificity comparable to ERCP. Therefore, it is reasonable to use EUS as the first method of choice in patients with suspected choledocholithiasis.
- 1 December 2009
- p. 5-9
[Endoscopic ultrasonography in the diagnosis of choledocholithiasis].
Endoscopic retrograde cholangiopancreatography (ERCP) has been considered a gold standard in the diagnosis of choledocholithiasis; however, the incidence of complications is high. In literature reports, the morbidity rate ranges from 5% to 19% and mortality rate from 0.1% to 1.3%, therefore an effective but less invasive new method of diagnosing choledocholithiasis is required. In a number of trials, endoscopic ultrasonography (EUS) has been shown to be a less invasive method with excellent sensitivity of 94% and specificity of 95%. The aim of this study was to estimate the sensitivity and specificity of EUS in patients with suspected choledocholithiasis and to establish its role in the algorithm for diagnosing choledocholithiasis. Patient files were retrospectively reviewed in 209 patients with a clinical picture and ultrasonography findings suggestive of choledocholithiasis, admitted to Sestre milosrdnice University Hospital during a six-month period (Sep 1, 2007 - Feb 29, 2008) and submitted to ERCP within 72 hours of admission. In 125 patients with abdominal ultrasonography findings suggestive of choledocholithiasis (biliary obstruction without clear evidence of calculi), EUS was performed before ERCR. Choledocholithiasis or biliary sludge was identified in 66 (62.3%) patients, 29 (27.3%) patients were free from biliary abnormalities, and 11 (10.4%) patients had stenosis of different etiology. In 64 of 66 (96.9%) patients, the diagnosis was confirmed by ERCP. Another two (3.1%) patients had no evidence of choledocholithiasis on ERCP. There were no complications related to EUS. EUS is an effective method for diagnosing choledocholithiasis with a sensitivity and specificity comparable to ERCP. Therefore, it is reasonable to use EUS as the first method of choice in patients with suspected choledocholithiasis.
- 1 December 2009
- p. 29-37
[Evaluation of upper gastrointestinal submucosal lesions by endoscopic ultrasonography].
Endoscopy is an established method for diagnosing gastrointestinal tract diseases, however, suspected subepithelial lesions usually cannot be appropriately evaluated by this technique alone. The prevalence of suspected submucosal gastric lesions at routine endoscopy has been estimated to 0.5%-1%. In this review, we evaluated the role of endoscopic ultrasonography (EUS) in the diagnosis of and management strategy for submucosal lesions. EUS has emerged as the most reliable investigative procedure of choice for evaluating submucosal tumors. EUS is the method of choice to differentiate between true intramural tumors and lesions caused by extraluminal compressions due to normal or pathologic structures. It can determine the originating layer(s) of intramural lesions; can differentiate echogenicity (anechoic, hypoechoic, hyperechoic, isoechoic), vascularity, size, shape, and border characteristics. Some endoscopic findings (color, consistency, mobility, 'pillow sign') can be helpful in narrowing the differential diagnosis. On the other hand, determination of the histologic layer and the internal echo patterns of some submucosal tumors are also predictive of benign or malignant tumors. EUS can provide an accurate diagnosis in 80% of patients with benign lesions and 64% of those with malignant lesions. Hypoechoic lesions in the 3rd and 4th layer are most prone to misclassification. If these cannot be differentiated exactly, EUS can serve as a guide on fine needle aspiration (FNA) biopsy or histologic core biopsies, providing samples for cytologic or histologic analysis. After that, the endoscopist can decide whether the lesion should be periodically followed up, or removed by endoscopy, endoscopic submucosal resection (EMR) or surgery.
- 1 December 2009
- p. 29-37
[Evaluation of upper gastrointestinal submucosal lesions by endoscopic ultrasonography].
Endoscopy is an established method for diagnosing gastrointestinal tract diseases, however, suspected subepithelial lesions usually cannot be appropriately evaluated by this technique alone. The prevalence of suspected submucosal gastric lesions at routine endoscopy has been estimated to 0.5%-1%. In this review, we evaluated the role of endoscopic ultrasonography (EUS) in the diagnosis of and management strategy for submucosal lesions. EUS has emerged as the most reliable investigative procedure of choice for evaluating submucosal tumors. EUS is the method of choice to differentiate between true intramural tumors and lesions caused by extraluminal compressions due to normal or pathologic structures. It can determine the originating layer(s) of intramural lesions; can differentiate echogenicity (anechoic, hypoechoic, hyperechoic, isoechoic), vascularity, size, shape, and border characteristics. Some endoscopic findings (color, consistency, mobility, 'pillow sign') can be helpful in narrowing the differential diagnosis. On the other hand, determination of the histologic layer and the internal echo patterns of some submucosal tumors are also predictive of benign or malignant tumors. EUS can provide an accurate diagnosis in 80% of patients with benign lesions and 64% of those with malignant lesions. Hypoechoic lesions in the 3rd and 4th layer are most prone to misclassification. If these cannot be differentiated exactly, EUS can serve as a guide on fine needle aspiration (FNA) biopsy or histologic core biopsies, providing samples for cytologic or histologic analysis. After that, the endoscopist can decide whether the lesion should be periodically followed up, or removed by endoscopy, endoscopic submucosal resection (EMR) or surgery.
- 1 December 2009
- p. 39-42
[The role of endoscopic ultrasonography in the evaluation of pancreatic cancer].
Pancreatic cancer has a dismal prognosis and complete surgical removal remains the only potential curative treatment. The principle goal of preoperative evaluation is to identify patients with potentially resectable disease while avoiding surgical exploration in those with unresectable disease. There is no evidence-based consensus on the optimal preoperative imaging assessment of patients with suspected pancreatic cancer. Because of its widespread availability, computed tomography (CT) is usually the initial study for this indication, although endoscopic ultrasonography (EUS) is the most sensitive imaging modality for the detection of pancreatic masses. Due to anatomical limitations, CT and magnetic resonance (MR) are superior to EUS for detection of metastatic disease. EUS is superior to CT and angiography for detection of tumor invasion of the portal vein or confluence. Most studies found no significant differences between EUS, CT and MRI in determination of pancreatic cancer resectability. The optimal place of EUS within the diagnostic algorithm remains dependent on local referral modalities and availability.
- 1 December 2009
- p. 39-42
[The role of endoscopic ultrasonography in the evaluation of pancreatic cancer].
Pancreatic cancer has a dismal prognosis and complete surgical removal remains the only potential curative treatment. The principle goal of preoperative evaluation is to identify patients with potentially resectable disease while avoiding surgical exploration in those with unresectable disease. There is no evidence-based consensus on the optimal preoperative imaging assessment of patients with suspected pancreatic cancer. Because of its widespread availability, computed tomography (CT) is usually the initial study for this indication, although endoscopic ultrasonography (EUS) is the most sensitive imaging modality for the detection of pancreatic masses. Due to anatomical limitations, CT and magnetic resonance (MR) are superior to EUS for detection of metastatic disease. EUS is superior to CT and angiography for detection of tumor invasion of the portal vein or confluence. Most studies found no significant differences between EUS, CT and MRI in determination of pancreatic cancer resectability. The optimal place of EUS within the diagnostic algorithm remains dependent on local referral modalities and availability.
- 1 January 2005
- Vol. 59 (5) , 453-61
[Hepatitis C--treatment of untreated (naive) patients].
The most important therapeutic advance in recent years considering chronic HCV infection has occurred with the introduction of pegylated interferon (PEG IFN) in the combination therapy with ribavirin, which results in better sustained virologic response (SVR). Although an SVR is difficult to correlate with improved survival because of the necessity for long-term follow up, the absence of detectable serum HCV RNA has been associated with resolution of liver injury, reduction in hepatic fibrosis, and a low likelihood of a relapse of the HCV infection. Two large pivotal trials examined the efficacy of PEG IFN plus ribavirin in the treatment of chronic HCV infection. Overall, PEG IFN plus ribavirin was more effective than the standard interferon-ribavirin combination. SVR rates were similar with both forms of PEG IFN (PEG IFN alfa-2a and PEG IFN alfa-2b) when used in combination with ribavirin. SVR rates of 42% and 46% were achieved in patients with genotype 1 compared to rates of 76% and 82% in patients with genotypes 2 and 3. Factors associated with successful therapy included genotypes other than 1, lower baseline viral levels, less fibrosis or inflammation on liver biopsy, and lower body weight or body surface area. Twenty four weeks of treatment with a combination of PEG IFN and ribavirin appears to be sufficient for patients infected with genotypes 2 and 3, while patients with genotype 1 need 48 weeks of treatment. Early virologic response (EVR), defined as undetectable HCV RNA or a minimum 2 log decrease in viral load (relative to baseline) after the first 12 weeks of treatment, is predictive of SVR and should be a routine part of monitoring patients with genotype 1. Patients who fail to achieve an EVR have only a small chance of achieving an SVR, therefore treatment should be discontinued after 12 weeks. It is also recommended to treat patients with acute hepatitis C to reduce the risk of developing chronic infection. Treatment should start 12 weeks after the onset of symptoms and includes 24 weeks of monotherapy with PEG IFN.
- 1 January 2005
- Vol. 59 (5) , 453-61
[Hepatitis C--treatment of untreated (naive) patients].
The most important therapeutic advance in recent years considering chronic HCV infection has occurred with the introduction of pegylated interferon (PEG IFN) in the combination therapy with ribavirin, which results in better sustained virologic response (SVR). Although an SVR is difficult to correlate with improved survival because of the necessity for long-term follow up, the absence of detectable serum HCV RNA has been associated with resolution of liver injury, reduction in hepatic fibrosis, and a low likelihood of a relapse of the HCV infection. Two large pivotal trials examined the efficacy of PEG IFN plus ribavirin in the treatment of chronic HCV infection. Overall, PEG IFN plus ribavirin was more effective than the standard interferon-ribavirin combination. SVR rates were similar with both forms of PEG IFN (PEG IFN alfa-2a and PEG IFN alfa-2b) when used in combination with ribavirin. SVR rates of 42% and 46% were achieved in patients with genotype 1 compared to rates of 76% and 82% in patients with genotypes 2 and 3. Factors associated with successful therapy included genotypes other than 1, lower baseline viral levels, less fibrosis or inflammation on liver biopsy, and lower body weight or body surface area. Twenty four weeks of treatment with a combination of PEG IFN and ribavirin appears to be sufficient for patients infected with genotypes 2 and 3, while patients with genotype 1 need 48 weeks of treatment. Early virologic response (EVR), defined as undetectable HCV RNA or a minimum 2 log decrease in viral load (relative to baseline) after the first 12 weeks of treatment, is predictive of SVR and should be a routine part of monitoring patients with genotype 1. Patients who fail to achieve an EVR have only a small chance of achieving an SVR, therefore treatment should be discontinued after 12 weeks. It is also recommended to treat patients with acute hepatitis C to reduce the risk of developing chronic infection. Treatment should start 12 weeks after the onset of symptoms and includes 24 weeks of monotherapy with PEG IFN.
- 1 January 2003
- Vol. 57 (3) , 189-99
[Non-alcoholic steatohepatitis].
Nonalcoholic steatohepatitis (NASH) is a condition characterized histologically by macrovesicular steatosis and lobular hepatitis with necrosis or ballooning degeneration and/or fibrosis--a picture resembling alcoholic hepatitis, in the absence of alcohol abuse. Most patients with NASH are asymptomatic, and the disease is detected incidentally. The most common signs of NASH are hepatomegaly and laboratory abnormalities, which include a 2-4-fold elevation of serum aminotransferase levels, while other liver function test results are usually normal. Most patients with NASH are obese, many have diabetes mellitus, hypercholesterolemia, or hypertriglyceridemia. NASH has also been associated with a number of metabolic derrangements, conditions, surgical procedures, and drug treatments. The pathogenesis of NASH is poorly understood, but lipid peroxidation and oxidative stress seem to be the leading culprits. The natural history of NASH is unknown, but it seems to be a stable disease in most patients. Still, the progress to cirrhosis is possible. There is no established treatment for NASH. Treatment is usually directed towards optimizing body weight, and pharmacologic agents are mostly experimentally used. Orthotopic liver transplantation is the treatment of choice for end-stage liver disease secondary to NASH.
- 1 January 2003
- Vol. 57 (3) , 189-99
[Non-alcoholic steatohepatitis].
Nonalcoholic steatohepatitis (NASH) is a condition characterized histologically by macrovesicular steatosis and lobular hepatitis with necrosis or ballooning degeneration and/or fibrosis--a picture resembling alcoholic hepatitis, in the absence of alcohol abuse. Most patients with NASH are asymptomatic, and the disease is detected incidentally. The most common signs of NASH are hepatomegaly and laboratory abnormalities, which include a 2-4-fold elevation of serum aminotransferase levels, while other liver function test results are usually normal. Most patients with NASH are obese, many have diabetes mellitus, hypercholesterolemia, or hypertriglyceridemia. NASH has also been associated with a number of metabolic derrangements, conditions, surgical procedures, and drug treatments. The pathogenesis of NASH is poorly understood, but lipid peroxidation and oxidative stress seem to be the leading culprits. The natural history of NASH is unknown, but it seems to be a stable disease in most patients. Still, the progress to cirrhosis is possible. There is no established treatment for NASH. Treatment is usually directed towards optimizing body weight, and pharmacologic agents are mostly experimentally used. Orthotopic liver transplantation is the treatment of choice for end-stage liver disease secondary to NASH.
- 1 January 2003
- Vol. 57 (3) , 207-19
[Primary sclerosing cholangitis--diagnosis and therapy].
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown origin, characterized by inflammation, fibrosis, and obliteration of bile ducts, which ultimately results in biliary cirrhosis. The condition most commonly affects intrahepatic and extrahepatic bile ducts together, but sometimes only intrahepatic or extrahepatic ducts are involved. PSC is often associated with inflammatory bowel disease, especially ulcerative colitis. The majority of patients are initially asymptomatic, and identified on the basis of elevated serum levels of alkaline phosphatase or gamma-glutamyl transpeptidase, especially while screening patients with ulcerative colitis. Diagnosis is based on characteristic cholangiographic appearance with focal bile duct dilatations proximal to areas of stricturing that produce a beaded appearance. Ursodeoxycholic acid is most effective medical therapy, with other symptomatic measures, while liver transplantation is the treatment of choice for patients with advanced liver disease.
- 1 January 2003
- Vol. 57 (3) , 207-19
[Primary sclerosing cholangitis--diagnosis and therapy].
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown origin, characterized by inflammation, fibrosis, and obliteration of bile ducts, which ultimately results in biliary cirrhosis. The condition most commonly affects intrahepatic and extrahepatic bile ducts together, but sometimes only intrahepatic or extrahepatic ducts are involved. PSC is often associated with inflammatory bowel disease, especially ulcerative colitis. The majority of patients are initially asymptomatic, and identified on the basis of elevated serum levels of alkaline phosphatase or gamma-glutamyl transpeptidase, especially while screening patients with ulcerative colitis. Diagnosis is based on characteristic cholangiographic appearance with focal bile duct dilatations proximal to areas of stricturing that produce a beaded appearance. Ursodeoxycholic acid is most effective medical therapy, with other symptomatic measures, while liver transplantation is the treatment of choice for patients with advanced liver disease.
- 1 January 2002
- Vol. 56 (1)
[Clinical features and diagnosis of inflammatory bowel disease].
The inflammatory bowel disease is common term for heterogenous group of the chronic recidivant idiopathic diseases with bowel inflammation as a common sign. Although within common term, traditionally we distinguish two diseases, Chrohns disease (CD) and ulcerative colitis (UC), in certain clinical situations those terms are not sufficient to describe all variants of inflammatory bowel diseases. Today increasingly, we have more and more knowledge about clinical, immunological, genetical heterogenicity in Crohns disease and ulcerative colitis. New evidences advocate theory that IBD represents folding subgroups of inflammatory bowel disorders in particular continuity with CD and UC as extremes of one spectrum.
- 1 January 2002
- Vol. 56 (1)
[Clinical features and diagnosis of inflammatory bowel disease].
The inflammatory bowel disease is common term for heterogenous group of the chronic recidivant idiopathic diseases with bowel inflammation as a common sign. Although within common term, traditionally we distinguish two diseases, Chrohns disease (CD) and ulcerative colitis (UC), in certain clinical situations those terms are not sufficient to describe all variants of inflammatory bowel diseases. Today increasingly, we have more and more knowledge about clinical, immunological, genetical heterogenicity in Crohns disease and ulcerative colitis. New evidences advocate theory that IBD represents folding subgroups of inflammatory bowel disorders in particular continuity with CD and UC as extremes of one spectrum.